Please login to the form below

Not currently logged in
Email:
Password:

Boehringer appoints Paul Fonteyne to lead US operations

He takes over from J Martin Carroll as president and CEO of Boehringer Ingelheim USA

Boehringer Ingelheim US CEO Paul FonteyneBoehringer Ingelheim has promoted Paul Fonteyne to president and CEO of its US operations.

He takes over from J Martin Carroll, who will remain with the company in a corporate strategy and development role.

"Change is a necessary and healthy part of any successful company," said Carroll. "After nine years as president and CEO, it was time to let others take the lead on the day-to-day management of the company's US operations.

“I have worked with Paul for more than 15 years, and am confident that his depth and breadth of experience, combined with his passion for finding new ways to bring medicines to patients makes him well-suited to take on this role and help lead the company to even greater success.”

Fonteyne was formerly corporate senior vice president with responsibility for leading the global marketing strategy supporting Boehringer's prescription medicines business.

"I am excited to be given the opportunity to lead the US operations," said Fonteyne. "I believe this company is stronger now than at any point in its 126 year history.

“I look forward to working with my colleagues in the US and globally to bring the best ideas to bear so that we may continue delivering on our commitment to bring more health to patients and their families."

25th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...